Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients

CONCLUSIONS: In moderate to severe COPD patients, FDCs of aclidinium/formoterol improved respiratory symptoms compared with placebo and monotherapies over 6 months.

Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Jones, P., D'Urzo, A., Rennard, S., Molins, E., Mergel, V., Caracta, C., Leselbaum, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research